LILRB1 and neoplasm: There are limited studies on improving the tumor‐phagocytosis capability of macrophages by blocking PD‐L1‐PD‐1, MHC‐I‐LILRB1, and CD24‐Siglec‐10 phagocytic immune checkpoint.